SCHEMBL7005000

SCHEMBL7005000

CCOC(=O)CCN(C(c1ccccc1)c1ccccc1)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 5/20 0.50
NFE2L2 Q16236 3/20 0.50
TAS2R14 Q9NYV8 1/20 0.50
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
BMP1 P13497 5/20 0.45
CAMK2A Q9UQM7 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CAMK2G Q13555 1/20 0.44
ALOX15 P16050 1/20 0.43
DAGLA Q9Y4D2 1/20 0.43
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acrylic Acid Ethyl Ester SCHEMBL7003780 0.93 TAS2R14 (0.45) KEAP1NFE2L2TAS2R14KMT2AMEN1
SCHEMBL7003735 0.83 BMP1 (0.61) KEAP1NFE2L2BMP1
SCHEMBL6999742 0.81 BMP1 (0.65) KEAP1NFE2L2KMT2AMEN1CYP3A4
SCHEMBL9843107 0.80 SMN1; SMN2 (0.49) KEAP1NFE2L2KMT2AALDH1A1MAPK1
SCHEMBL7004788 0.79 BMP1 (0.66) TAS2R14KMT2ABMP1ALDH1A1MAPK1
SCHEMBL7001435 0.78 BMP1 (0.67) TAS2R14BMP1ALDH1A1
SCHEMBL7003241 0.77 KEAP1 (0.61) KEAP1NFE2L2CYP3A4MAPTCYP2C9
SCHEMBL7004444 0.76 BMP1 (0.71) KEAP1NFE2L2CYP3A4MAPTCYP2C9
SCHEMBL7112761 0.75 BMP1 (0.72) TAS2R14KMT2AMAPTBMP1ALDH1A1
SCHEMBL7003476 0.74 BMP1 (0.69) TAS2R14BMP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191309-A1 N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production HO WEN-BIN (US) 2003-10-09 US disclosed
EP-1154992-A4 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN INC (US) 2003-05-28 EP disclosed
US-6506936-B1 Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases FIBROGEN, INC. 2003-01-14 US disclosed
EP-1154992-A1 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN, INC. (US) 2001-11-21 EP disclosed
WO-2000050390-A1 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN, INC. (US) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191309-A1 N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production MMP1, MMP13, COL14A1 KEAP1 880/4885NFE2L2 1898/4885TAS2R14 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.